Quantcast

Latest Antiandrogens Stories

2014-06-02 08:30:44

Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer...

2014-05-19 12:46:46

European Society of Cardiology TOPCAT fails to meet primary endpoint but post-hoc analysis shows benefit in patients from Americas Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas. The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting...

2014-05-14 16:29:31

- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin and JNJ-42756493 RARITAN, N.J., May 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...

2014-05-14 16:29:25

Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced that eight enzalutamide abstracts will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3 in Chicago. http://photos.prnewswire.com/prnvar/20140416/84970 The...

2014-04-10 09:55:23

Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitaliization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and...

2014-03-27 08:33:33

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/djkgl4/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide,...

2014-02-24 12:26:47

DALLAS, February 24, 2014 /PRNewswire/ -- ReportsnReports.com offers "Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" and "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the treatment Paradigm of Prostate Cancer" research reports in its store. Japan biosimilar market will enter new phase of biosimilars with first 'mab' approval expected in 2014. This...

2014-02-06 08:28:18

TORONTO, Feb. 6, 2014 /CNW/ - Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec now have access to a therapy that can be used prior to chemotherapy. Effective February 3, 2014, the province has added ZYTIGA(®) (abiraterone acetate) to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).(1) "ZYTIGA(® )provides men and health care professionals with a...

2013-09-25 11:02:09

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. The study, published Sept. 24 in Lancet Oncology, was led by Ethan Basch, MD, director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center. Researchers measured the pain and quality of life...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.